News

April 23, 2018April 23, 2018

Add-on Lupuzor Fails Primary Goal but Shows Some Positive Results in Phase 3 Trial for SLE

News

Lupuzor (rigerimod, or IPP-201101) combined with standard therapy did not demonstrate a statistically significant response rate in systemic lupus erythematosus (SLE) patients over standard care alone, failing the primary goal of ... Read more

April 20, 2018April 20, 2018

Lupus Research Alliance Awards 9 Grants for Innovative Studies

News

The Lupus Research Alliance recently announced the nine winners of its Novel Research Grants, to support innovative research on lupus. The grants support research into the complexity of lupus from ... Read more

April 18, 2018April 18, 2018

Atacicept Reduces Disease Burden in Lupus Patients with High Disease Activity, Study Shows

News

Treatment with 150 mg atacicept significantly improves outcomes in systemic lupus erythematosus (SLE) patients with high disease activity, data from a Phase 2b clinical trial show. The results of ... Read more

April 16, 2018April 16, 2018

New Way of Diagnosing SLE and Predicting Its Course Better Than Existing Tests, Study Says

News

A new test looking at the presence of 26 autoantibodies — antibodies targeting a person’s own healthy proteins — is better at diagnosing systemic lupus erythematosus (SLE) and predicting ... Read more

April 13, 2018April 13, 2018

Lenabasum, Investigational Therapy for Lupus, Advances to Phase 2 Clinical Trial

News

A Phase 2 clinical trial testing a Corbus Pharmaceuticals’ synthetic cannabinoid derivative – lenabasum (JBT-101) – for lupus patients is underway. The therapy has no psychotropic properties and is intended ... Read more

April 11, 2018April 11, 2018

Harmless Bacteria in the Body May Trigger Autoimmunity in Some People, Study Reports

News

Harmless bacteria that live in the skin, mouth and gut may trigger autoimmunity in people who are genetically disposed to it, according to a study with lupus implications. This ... Read more

April 9, 2018April 10, 2018

Atacicept, a B-cell Targeting Protein, Reduced Lupus Flares in Clinical Trials

News

Treatment with atacicept — a protein that targets the immune system — significantly reduced disease flares in patients with systemic lupus erythematosus (SLE), data from EMD Serono‘s Phase 2 ... Read more

April 6, 2018April 6, 2018

Foundation for the NIH Announces Chen is Winner of 2018 Lurie Prize in Biomedical Sciences

News

Zhijian “James” Chen, PhD recently was awarded the 2018 Lurie Prize in Biomedical Sciences by the Foundation for the National Institutes of Health (FNIH) for his discovery of how ... Read more

April 4, 2018April 4, 2018

ImmuPharma Expects Top-Line Results of Lupuzor Phase 3 Trial by Mid-April

News

Top-line results of ImmuPharma’s Phase 3 clinical trial testing Lupuzor (rigerimod) as a systemic lupus erythematosus (SLE) treatment are expected by mid-April, according to the company. ImmuPharma also announced that database ... Read more

April 2, 2018April 2, 2018

Targeting Key Protein in Inflammation Could Prevent Lupus Kidney Damage, Study Suggests

News

Suppressing the key inflammatory protein iRhom2 reduced inflammation and prevented kidney scarring in mice susceptible to developing lupus, a study suggests. This approach could be the basis of new treatments ... Read more

Pin It on Pinterest